AR046213A1 - Forma de presentacion del naproxeno sodico - Google Patents
Forma de presentacion del naproxeno sodicoInfo
- Publication number
- AR046213A1 AR046213A1 ARP040103936A ARP040103936A AR046213A1 AR 046213 A1 AR046213 A1 AR 046213A1 AR P040103936 A ARP040103936 A AR P040103936A AR P040103936 A ARP040103936 A AR P040103936A AR 046213 A1 AR046213 A1 AR 046213A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- tablet core
- tablet
- naproxen
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un comprimido no efervescente de naproxeno sódico, que consta de un núcleo de comprimido y si se desea de un revestimiento de azúcar o de una película, donde el núcleo del comprimido, respecto al peso del núcleo del comprimido, se compone de un 30 hasta de un 99% en peso de naproxeno sódico y de un 70 hasta de un 1% en peso de componente de materia auxiliar, que incluye como mínimo una sustancia auxiliar básica, posee una dureza suficiente, es comparativamente pequeno y conduce a un aumento del nivel de sangre especialmente rápido y con ello a una acción analgésica. Reivindicación 41: Procedimiento para la fabricación de un comprimido no efervescente para la administración oral de naproxeno sódico, que comprende un núcleo de naproxeno y si se desea un recubrimiento de azúcar o de una película sobre el núcleo del comprimido, donde el núcleo del comprimido respecto al peso del núcleo del comprimido, consta de 30 a 99% en peso de naproxeno sódico y de 70 a 1% en peso de componente de agente auxiliar, respecto al peso del núcleo del comprimido, que se caracteriza porque una mezcla de naproxeno sódico y el componente de agente auxiliar se comprime al núcleo del comprimido y si se desea, los núcleos de los comprimidos se recubren de una película o de azúcar.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH18482003 | 2003-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046213A1 true AR046213A1 (es) | 2005-11-30 |
Family
ID=34529359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103936A AR046213A1 (es) | 2003-10-30 | 2004-10-28 | Forma de presentacion del naproxeno sodico |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070134317A1 (es) |
EP (1) | EP1684728B1 (es) |
JP (1) | JP2007509862A (es) |
AR (1) | AR046213A1 (es) |
AT (1) | ATE442840T1 (es) |
BR (1) | BRPI0415624A (es) |
CA (1) | CA2543709A1 (es) |
CR (1) | CR8406A (es) |
DE (1) | DE602004023220D1 (es) |
EC (1) | ECSP066587A (es) |
ES (1) | ES2333332T3 (es) |
PA (1) | PA8616101A1 (es) |
PE (1) | PE20050445A1 (es) |
UY (1) | UY28583A1 (es) |
WO (1) | WO2005041938A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008500288A (ja) * | 2004-05-28 | 2008-01-10 | イメイジノット ピーティーワイ エルティーディー | 経口治療用化合物の供給系 |
RU2403033C2 (ru) | 2005-03-22 | 2010-11-10 | Лозан Фарма Гмбх | Солюбилизированный ибупрофен |
EP3449928A1 (en) | 2005-11-28 | 2019-03-06 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
GB201506755D0 (en) * | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
US11278506B2 (en) * | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
JP7163014B2 (ja) * | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | 感冒薬 |
JP7163015B2 (ja) * | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | 経口固形組成物 |
US11779541B2 (en) | 2019-03-26 | 2023-10-10 | Johnson & Johnson Consumer Inc. | Immediate release dosage form |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
US5034416A (en) * | 1988-01-19 | 1991-07-23 | Smith Walton J | Carboxylic acid compositions |
PT96229B (pt) * | 1989-12-22 | 1998-06-30 | Syntex Pharma Int | Processo para a preparacao de composicoes farmaceuticas em po, secas por pulverizacao, directamente compressiveis em comprimidos, contendo naproxeno ou naproxeno sodico |
US5358717A (en) * | 1989-12-22 | 1994-10-25 | Syntex (U.S.A.) Inc. | Directly-compressible naproxen or naproxen sodium compositions |
IT1272149B (it) * | 1993-03-26 | 1997-06-11 | Zambon Spa | Composizione farmeceutiche ad attivita' analgesica |
GB9603699D0 (en) * | 1996-02-21 | 1996-04-17 | Boots Co Plc | Therapeutic composition |
US5948787A (en) * | 1997-02-28 | 1999-09-07 | Alza Corporation | Compositions containing opiate analgesics |
JPH10298072A (ja) * | 1997-04-17 | 1998-11-10 | Panacea Biotec Ltd | 非ステロイド性抗炎症剤の遷移金属錯体 |
NZ333474A (en) * | 1998-01-02 | 1999-06-29 | Mcneil Ppc Inc | A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat |
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
US6383515B2 (en) * | 1999-05-28 | 2002-05-07 | Sawyer Maryjean | Solvent system for enhancing solubility |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2002083110A2 (en) * | 2001-04-10 | 2002-10-24 | Zagros Pharma, Inc. | Animal model for evaluating analgesics |
US20020192161A1 (en) * | 2001-04-10 | 2002-12-19 | Fahkreddin Jamali | Animal model for evaluating analgesics |
-
2004
- 2004-10-27 UY UY28583A patent/UY28583A1/es not_active Application Discontinuation
- 2004-10-27 PE PE2004001035A patent/PE20050445A1/es not_active Application Discontinuation
- 2004-10-28 PA PA20048616101A patent/PA8616101A1/es unknown
- 2004-10-28 AR ARP040103936A patent/AR046213A1/es not_active Application Discontinuation
- 2004-10-29 JP JP2006537031A patent/JP2007509862A/ja active Pending
- 2004-10-29 BR BRPI0415624-2A patent/BRPI0415624A/pt not_active IP Right Cessation
- 2004-10-29 ES ES04761983T patent/ES2333332T3/es active Active
- 2004-10-29 AT AT04761983T patent/ATE442840T1/de not_active IP Right Cessation
- 2004-10-29 CA CA000000008A patent/CA2543709A1/en not_active Abandoned
- 2004-10-29 US US10/577,197 patent/US20070134317A1/en not_active Abandoned
- 2004-10-29 DE DE602004023220T patent/DE602004023220D1/de active Active
- 2004-10-29 WO PCT/CH2004/000655 patent/WO2005041938A1/en active Application Filing
- 2004-10-29 EP EP04761983A patent/EP1684728B1/en active Active
-
2006
- 2006-05-15 CR CR8406A patent/CR8406A/es not_active Application Discontinuation
- 2006-05-29 EC EC2006006587A patent/ECSP066587A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007509862A (ja) | 2007-04-19 |
DE602004023220D1 (de) | 2009-10-29 |
ATE442840T1 (de) | 2009-10-15 |
PA8616101A1 (es) | 2005-08-04 |
UY28583A1 (es) | 2005-05-31 |
ECSP066587A (es) | 2006-10-17 |
EP1684728A1 (en) | 2006-08-02 |
WO2005041938A1 (en) | 2005-05-12 |
CR8406A (es) | 2008-04-25 |
CA2543709A1 (en) | 2005-05-12 |
PE20050445A1 (es) | 2005-06-18 |
US20070134317A1 (en) | 2007-06-14 |
ES2333332T3 (es) | 2010-02-19 |
EP1684728B1 (en) | 2009-09-16 |
BRPI0415624A (pt) | 2006-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
GT200600474A (es) | Composiciones farmaceuticas solidas que contienen pregabalina | |
GT200600295A (es) | Una formulacion solida de dosificacion farmaceutica | |
CR8406A (es) | Forma de administracion del naproxeno sodico | |
CO6501159A2 (es) | Formulaciones farmaceuticas de liberación controlada de nitazoxanida | |
AR081760A1 (es) | Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento | |
CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
PE20080765A1 (es) | Formas de dosificacion farmaceutica | |
CO5190672A1 (es) | Composicion para la dosificacion oral, de disolucion instantanea | |
AR066585A1 (es) | Nuevo producto y su uso y fabricacion | |
PE20120476A1 (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
DE60132077D1 (de) | Vitaminzusammenstellung mit verzögerter freigabe | |
AR064540A1 (es) | Dispositivo de inhalacion para medicamentos en forma de polvo | |
CR7500A (es) | Formas de dosificacion de azitromicida con efectos secundarios reducidos | |
AR054064A1 (es) | Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas | |
AR065809A1 (es) | Formulaciones farmaceuticas que contienen un inhibidor sglt2 | |
ECSP066553A (es) | Formas de administración masticables, no comprimidas dosificadas individualmente. | |
CL2010001275A1 (es) | Metodo para producir un producto intermedio compactado de bibw 2992 ma2 que comprende una etapa de compactacion por rodillos de bibw 2992 ma2 u opcionalmente en una premezcla con 0-1,0% de lubricante en un mezclador de caida libre o de volteo y una etapa de tamizado; producto intermedio compactado; comprimido. | |
AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
CR9626A (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato | |
UY27042A1 (es) | Combinación de agonistas de gaba e inhibidores de sorbitol deshidrogenasa | |
PA8616201A1 (es) | Composiciones farmaceuticas de liberacion sostenida | |
CR8059A (es) | Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas | |
AR073089A1 (es) | DERIVADOS DE (POLI)AMINOALQUILAMINOALQUILAMIDAS, ALQUIL-UREA O ALQUILSULFONAMIDA DE EPIPODOFILOTOXINA, UN PROCESO PARA PREPARARLOS, SU APLICACIoN EN TERAPIA COMO AGENTES ANTICANCER Y COMPOSICION FARMACEUTICA QUE LOS CONTIENEN. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |